Search research articles
Contact Us
Filters
Showing results (61-70 of 133) with videos related to
Page
of 14
Sort By:
Leukemia Research
|
April 15, 2008
Iron overload in myelodysplastic syndromes: a Canadian consensus guideline
Richard A Wells, Brian Leber, Rena Buckstein, et al.
British Journal of Haematology
|
June 29, 2011
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin
Myron S Czuczman, Julie M Vose, Thomas E Witzig, et al.
Leukemia & Lymphoma
|
January 9, 2014
Initial transfusion intensity predicts survival in myelodysplastic syndrome
Lap Shu Alan Chan, Roman Shapiro, Rena Buckstein, et al.
Journal of Geriatric Oncology
|
May 7, 2015
Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age
Shabbir M H Alibhai, Henriette Breunis, Narhari Timilshina, et al.
Leukemia & Lymphoma
|
April 6, 2011
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group
Rena Buckstein, John Kuruvilla, Neil Chua, et al.
Leukemia & Lymphoma
|
June 25, 2016
FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study
Lale Kostakoglu, Andre Goy, Giovanni Martinelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 2009
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial
David P Steensma, Maria R Baer, James L Slack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2006
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma
Rena Buckstein, Robert S Kerbel, Yuval Shaked, et al.
Leukemia & Lymphoma
|
February 18, 2011
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
C Tom Kouroukis, Louis A V Fernandez, Michael Crump, et al.
Hematological Oncology
|
May 1, 2018
Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with <sup>90</sup> Y ibritumomab tiuxetan in a phase II study
Neil L Berinstein, Nancy M Pennell, Rashmi Weerasinghe, et al.
Page
of 14
Search research articles
Search
Showing results (61-70 of 133) with videos related to
Sort By:
Page
of 14
Leukemia Research
|
April 15, 2008
Iron overload in myelodysplastic syndromes: a Canadian consensus guideline
Richard A Wells, Brian Leber, Rena Buckstein, et al.
British Journal of Haematology
|
June 29, 2011
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin
Myron S Czuczman, Julie M Vose, Thomas E Witzig, et al.
Leukemia & Lymphoma
|
January 9, 2014
Initial transfusion intensity predicts survival in myelodysplastic syndrome
Lap Shu Alan Chan, Roman Shapiro, Rena Buckstein, et al.
Journal of Geriatric Oncology
|
May 7, 2015
Quality of life and physical function in adults treated with intensive chemotherapy for acute myeloid leukemia improve over time independent of age
Shabbir M H Alibhai, Henriette Breunis, Narhari Timilshina, et al.
Leukemia & Lymphoma
|
April 6, 2011
Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group
Rena Buckstein, John Kuruvilla, Neil Chua, et al.
Leukemia & Lymphoma
|
June 25, 2016
FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study
Lale Kostakoglu, Andre Goy, Giovanni Martinelli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 17, 2009
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial
David P Steensma, Maria R Baer, James L Slack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2006
High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma
Rena Buckstein, Robert S Kerbel, Yuval Shaked, et al.
Leukemia & Lymphoma
|
February 18, 2011
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)
C Tom Kouroukis, Louis A V Fernandez, Michael Crump, et al.
Hematological Oncology
|
May 1, 2018
Management of newly diagnosed high-risk and intermediate-risk follicular lymphoma with <sup>90</sup> Y ibritumomab tiuxetan in a phase II study
Neil L Berinstein, Nancy M Pennell, Rashmi Weerasinghe, et al.
Page
of 14